Tochi M Okwuosa1, Elsayed Z Soliman2, Faye Lopez3, Kim A Williams4, Alvaro Alonso3, Keith C Ferdinand5. 1. Rush University School of Medicine, Chicago, IL. Electronic address: Tochukwu_M_Okwuosa@rush.edu. 2. Wake Forest University School of Medicine, Winston-Salem, NC. 3. University of Minnesota, Minneapolis, MN. 4. Rush University School of Medicine, Chicago, IL. 5. Tulane University School of Medicine, New Orleans, LA.
Abstract
BACKGROUND: Left ventricular hypertrophy (LVH) is a major independent predictor of cardiovascular disease (CVD) survival and is more prevalent in blacks than whites. In a large biracial population, we evaluated the ability of electrocardiography (ECG)-determined LVH (ECG-LVH) to reclassify CVD/coronary heart disease (CHD) events beyond traditional risk factors in blacks and whites. METHODS: The analysis included 14,489 participants (mean age 54 ± 5.7 years; 43.5% men; 26% black) from the ARIC cohort, with baseline (1987-1989) ECG, followed up for 10 years. Predicted risk for incident CVD and CHD were estimated using the 10-year Pooled Cohort and Framingham risk equations (base models 1A/1B), respectively. Models 2A and 2B included respective base model plus LVH by "any" of 10 traditional ECG-LVH criteria. Net reclassification improvement (NRI) was calculated, and the distribution of risk was compared using models 2A and 2B versus models 1A and 1B, respectively. RESULTS: There were 792 (5.5%) 10-year Pooled Cohort CVD events and 690 (4.8%) 10-year Framingham CHD events. Left ventricular hypertrophy defined by any criteria was associated with CVD and CHD events (hazard ratio [95% CI] 1.62 [1.38-1.90] and 1.56 [1.32-1.86], respectively]. Left ventricular hypertrophy did not significantly reclassify or improve C statistic in models 2A/B (C statistics 0.767/0.719; NRI = 0.001 [P = not significant]), compared with the base models 1A/B (C statistics 0.770/0.718), respectively. No racial interactions were observed. CONCLUSIONS: In this large cohort of black and white participants, ECG-LVH was associated with CVD/CHD risk but did not significantly improve CVD and CHD events risk prediction beyond the new Pooled Cohort and most used Framingham risk equations in blacks or whites.
BACKGROUND:Left ventricular hypertrophy (LVH) is a major independent predictor of cardiovascular disease (CVD) survival and is more prevalent in blacks than whites. In a large biracial population, we evaluated the ability of electrocardiography (ECG)-determined LVH (ECG-LVH) to reclassify CVD/coronary heart disease (CHD) events beyond traditional risk factors in blacks and whites. METHODS: The analysis included 14,489 participants (mean age 54 ± 5.7 years; 43.5% men; 26% black) from the ARIC cohort, with baseline (1987-1989) ECG, followed up for 10 years. Predicted risk for incident CVD and CHD were estimated using the 10-year Pooled Cohort and Framingham risk equations (base models 1A/1B), respectively. Models 2A and 2B included respective base model plus LVH by "any" of 10 traditional ECG-LVH criteria. Net reclassification improvement (NRI) was calculated, and the distribution of risk was compared using models 2A and 2B versus models 1A and 1B, respectively. RESULTS: There were 792 (5.5%) 10-year Pooled Cohort CVD events and 690 (4.8%) 10-year Framingham CHD events. Left ventricular hypertrophy defined by any criteria was associated with CVD and CHD events (hazard ratio [95% CI] 1.62 [1.38-1.90] and 1.56 [1.32-1.86], respectively]. Left ventricular hypertrophy did not significantly reclassify or improve C statistic in models 2A/B (C statistics 0.767/0.719; NRI = 0.001 [P = not significant]), compared with the base models 1A/B (C statistics 0.770/0.718), respectively. No racial interactions were observed. CONCLUSIONS: In this large cohort of black and white participants, ECG-LVH was associated with CVD/CHD risk but did not significantly improve CVD and CHD events risk prediction beyond the new Pooled Cohort and most used Framingham risk equations in blacks or whites.
Authors: Aditya Jain; Harikrishna Tandri; Darshan Dalal; Harjit Chahal; Elsayed Z Soliman; Ronald J Prineas; Aaron R Folsom; João A C Lima; David A Bluemke Journal: Am Heart J Date: 2010-04 Impact factor: 4.749
Authors: Mark H Drazner; Daniel L Dries; Ronald M Peshock; Richard S Cooper; Chris Klassen; Farhana Kazi; DuWayne Willett; Ronald G Victor Journal: Hypertension Date: 2005-06-06 Impact factor: 10.190
Authors: Randi E Foraker; Kathryn M Rose; Anna M Kucharska-Newton; Hanyu Ni; Chirayath M Suchindran; Eric A Whitsel Journal: Ann Epidemiol Date: 2011-04-23 Impact factor: 3.797
Authors: Parveen K Garg; Wesley T O'Neal; Yejin Mok; Gerardo Heiss; Joseph Coresh; Kunihiro Matsushita Journal: Am J Prev Med Date: 2018-11 Impact factor: 5.043
Authors: Lisandro D Colantonio; Christopher M Gamboa; Joshua S Richman; Emily B Levitan; Elsayed Z Soliman; George Howard; Monika M Safford Journal: Circulation Date: 2017-07-11 Impact factor: 29.690
Authors: Qiong-Ling Fan; Jia-Wei Wang; Shi-Lei Zhang; Tao Liu; Jun Zhao; Shu-Ping You Journal: Evid Based Complement Alternat Med Date: 2020-06-09 Impact factor: 2.629
Authors: Parveen K Garg; Wesley T O'Neal; Lin Y Chen; Laura R Loehr; Nona Sotoodehnia; Elsayed Z Soliman; Alvaro Alonso Journal: J Am Heart Assoc Date: 2018-04-12 Impact factor: 5.501